Company
Cellective Therapeutics
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
Cellective was acquired by Medimmune for proceeds of up to $175 million. Cellective was developing several new pharmaceuticals treating B Cell related cancers and immune diseases. The technology is based on research by Founder Tom Tedder, Chairman of Immunology at Duke University.
Loading relationship preview